Phibro Animal Health Corp (PAHC): R&D Expense
$24.55M
Year ended 2026-06-30
+0.2%
3-year compound annual growth
+6.7%
5-year compound annual growth
+8.3%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $24.55M | +3.5% | 2026-08-26, From 2025-07-01 |
| 2025-06-30 | $23.73M | -18.7% | 2026-08-26, From 2024-07-01 |
| 2024-06-30 | $29.19M | +19.7% | 2026-08-26, From 2023-07-01 |
| 2023-06-30 | $24.39M | +17.1% | 2025-08-27, From 2022-07-01 |
| 2022-06-30 | $20.83M | +17.3% | 2024-08-28, From 2021-07-01 |
| 2021-06-30 | $17.76M | +29.3% | 2023-08-30, From 2020-07-01 |
| 2020-06-30 | $13.74M | +13.6% | 2022-08-24, From 2019-07-01 |
| 2019-06-30 | $12.09M | +21.0% | 2021-08-25, From 2018-07-01 |
| 2018-06-30 | $10.00M | +5.9% | 2020-08-26, From 2017-07-01 |
| 2017-06-30 | $9.44M | -14.4% | 2019-08-27, From 2016-07-01 |
| 2016-06-30 | $11.03M | +16.0% | 2018-08-27, From 2015-07-01 |
| 2015-06-30 | $9.51M | +15.8% | 2017-08-30, From 2014-07-01 |
| 2014-06-30 | $8.21M | +23.7% | 2016-08-29, From 2013-07-01 |
| 2013-06-30 | $6.64M | -7.7% | 2015-09-10, From 2012-07-01 |
| 2012-06-30 | $7.19M | n/a | 2014-09-18, From 2011-07-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Phibro Animal Health Corp (PAHC) | 2026-06-30 | $24.55M | +3.5% |
| Alkermes plc. (ALKS) | 2025-12-31 | $323.96M | +32.1% |
| PTC Therapeutics, Inc. (PTCT) | 2025-12-31 | $455.25M | -14.8% |
| Indivior Pharmaceuticals, Inc. (INDV) | 2025-12-31 | $97.00M | -9.3% |
| Acadia Pharmaceuticals Inc (ACAD) | 2025-12-31 | $328.80M | +8.4% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | $1.52B | +89.2% |
| Royalty Pharma plc (RPRX) | 2025-12-31 | $452.00M | n/m |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2025-12-31 | $388.52M | +64.1% |
| Ionis Pharmaceuticals Inc (IONS) | 2025-12-31 | $915.62M | +1.6% |
Compare PAHC, ALKS, PTCT, INDV side by side · Screen every company in Pharmaceutical Preparations ↗